How do you choose between atezolizumab, bevacizumab, carboplatin, paclitaxel (IMpower 150) vs. pembrolizumab plus chemotherapy (KEYNOTE 189) in patients with metastatic NSCLC?

This is a great question. As we are all well aware, the combination of chemotherapy and immunotherapy has become a standard of care for some patients with advanced non-squamous NSCLC. Both the IMPOWER trial published by Socinski et al. in NEJM and the KEYNOTE 189 trial published by Gandhi et al. in ...